These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 20441723

  • 1. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
    Rapoport MJ, Mitchell RA, McCullagh S, Herrmann N, Chan F, Kiss A, Feinstein A, Lanctôt KL.
    J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R, da Silva Telles RM, Alves TC, Andrei AM, Rays J, Iosifescu DV, Wajngarten M.
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [Abstract] [Full Text] [Related]

  • 3. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M, Akhondzadeh S.
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [Abstract] [Full Text] [Related]

  • 5. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
    Rosenberg C, Lauritzen L, Brix J, Jørgensen JB, Kofod P, Bayer LB.
    Psychopharmacol Bull; 2007 Jul; 40(1):63-73. PubMed ID: 17285097
    [Abstract] [Full Text] [Related]

  • 6. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 7. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [Abstract] [Full Text] [Related]

  • 8. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P, Lönn SL, Overø KF.
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression.
    Wirz-Justice A, Bader A, Frisch U, Stieglitz RD, Alder J, Bitzer J, Hösli I, Jazbec S, Benedetti F, Terman M, Wisner KL, Riecher-Rössler A.
    J Clin Psychiatry; 2011 Jul; 72(7):986-93. PubMed ID: 21535997
    [Abstract] [Full Text] [Related]

  • 10. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
    Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS, Howland RH, Trivedi MH, Jain R, Greenwald S, Leuchter AF.
    J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 12. First episode of major depressive disorder and vascular factors in coronary artery disease patients: Baseline characteristics and response to antidepressant treatment in the CREATE trial.
    Habra ME, Baker B, Frasure-Smith N, Swenson JR, Koszycki D, Butler G, van Zyl LT, Lespérance F.
    J Psychosom Res; 2010 Aug; 69(2):133-41. PubMed ID: 20624511
    [Abstract] [Full Text] [Related]

  • 13. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T.
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A.
    J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
    [Abstract] [Full Text] [Related]

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 17. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U, Onder E.
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [Abstract] [Full Text] [Related]

  • 18. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD, Bodkin JA.
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [Abstract] [Full Text] [Related]

  • 19. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [Abstract] [Full Text] [Related]

  • 20. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML, Luo BY, Hu JB, Wang SS, Zhou WH, Wei N, Hu SH, Xu Y.
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.